69 results about "Aldosterone" patented technology

The present invention belongs to the technical field of chemical pharmaceuticals. Provided in the present invention are an aldosterone synthetase inhibitor, and a preparation method therefor and the use thereof.

The invention discloses a pyranopyridine compound as well as a preparation method, a pharmaceutical composition and application thereof. The invention provides a compound as shown in a formula (I), a pharmaceutically acceptable salt or a stereoisomer thereof, and the compound has a relatively strong inhibition effect on aldosterone synthetase, almost has no influence on cortisol synthetase, has high selectivity and relatively high safety, and can be used for preventing and / or treating various diseases related to aldosterone. # imgabs0 #

The invention relates to the technical field of medical detection, in particular to a method for detecting aldosterone, cortisol, deoxycorticosterone and cortisone in plasma through LC-MS / MS. The method comprises the following steps: (a) mixing a plasma sample with an internal standard solution to obtain a mixed solution; (b) adding the mixed solution into the magnetic bead suspension, sequentially carrying out adsorption, weak washing, strong washing and elution, and collecting an eluent; (c) carrying out liquid nitrogen blowing and redissolving on the eluent, and then carrying out LC-MS / MS detection; wherein the surfaces of the magnetic beads are modified with steroid adsorption groups, and the target detection objects are aldosterone, cortisol, deoxycorticosterone and cortisone. The detection method is convenient and simple, the detection efficiency is higher than that of a traditional method, and a feasible solution is provided for promoting popularization and application of the LC-MS / MS technology in clinical practice.

The invention relates to the technical field of medical detection, in particular to an endocrine hypertension screening method based on immunological analysis, which comprises the following steps: collecting a random urine sample, removing interferents by using a composite nano adsorbent, and synchronously detecting hormones such as aldosterone, methoxyadrenaline and cortisol and metabolites thereof by using a high-throughput immunity analyzer; integrating detection data based on a dynamic threshold algorithm to generate a screening report, carrying out weighted scoring on positive samples in combination with clinical features, screening high-risk candidate samples, carrying out 24-hour urine retest on the high-risk samples, and if a retest result is still positive, carrying out referral treatment to a specialized department for disease cause definite diagnosis; according to the method, the technical problems of complex sample treatment, low multi-step efficiency and high false positive rate in the prior art are solved, efficient and accurate screening of endocrine hypertension is realized, and reliable support is provided for early diagnosis and targeted treatment.

The invention relates to the technical field of medical treatment, in particular to a horizontal and vertical position aldosterone test interactive posture intelligent reminder which comprises a machine body. A posture monitoring sensor module, a patient test information input module, an intelligent reminding information generation module and a reminding module are arranged in the machine body; the posture monitoring sensor module is used for monitoring postures of a patient, including a lying position, a standing position and a standing position; the patient test information input module is used for inputting personal information and test related information of a patient; the intelligent reminding information generation module is based on the test posture and time requirements of the patient. Information interaction is achieved between a patient and the device, the device can remind the patient how to do, the device can know whether the patient completes the task according to the requirement and feed back the feedback after the patient completes the task according to the requirement according to reminding of the device, meanwhile, the test process is simplified, the patient visually knows the test process through the intelligent reminder, and confusion and forgetting are avoided.

Provided herein are methods of reducing the amount of AGT RNA and / or AGT protein in a subject having or at risk for heart failure, such as heart failure with reduced ejection fraction (HFrEF), heart failure with mid-range ejection fraction (HFmrEF), or heart failure with preserved ejection fraction (HFpEF), and, in particular instances, a subject who is, or is at risk of being, intolerant to treatment with a renin-angiotensin-aldosterone system (RAAS) inhibitor. Also provided herein are methods for treating heart failure (such as HFrEF, HFmrEF or HFpEF). Methods provided herein include administering to a subject an oligomeric agent containing a modified oligonucleotide containing a nucleobase sequence complementary to a sequence in an AGT nucleic acid, such as ION904. Further provided herein are pharmaceutical compositions containing ION904.

The present invention concerns selective renal denervation treatment of drug resistant hypertensive patients by correlating the patients' genetic panel by categorization and hierarchy according to patients' genetic variants within the functional genes for heart activity, for the renin-angiotensin aldosterone system, and for renal activity.

The invention provides an aldosterone antigen binding molecule and application thereof, and relates to the technical field of biology. The aldosterone antigen binding molecule is selected from a first antigen binding molecule containing CDR sequences as shown in SEQ ID NO.1 and SEQ ID NO.2 or a second antigen binding molecule containing CDR sequences as shown in SEQ ID NO.3 and SEQ ID NO.4. The aldosterone antigen binding molecule can bind an aldosterone antigen, and can be used for a method or a product for detecting aldosterone based on an immunological principle; the first antigen binding molecule and the second antigen binding molecule can also form an immune complex with a double-antibody sandwich structure with aldosterone, so that aldosterone is detected by a double-antibody sandwich principle.

The invention relates to the technical field of traditional Chinese medicines, in particular to application of a traditional Chinese medicine composition in preparation of medicines for preventing and treating hypertension. The traditional Chinese medicine composition comprises sedum sarmentosum, seaweed, oyster, hawthorn, herba siegesbeckiae, schisandra chinensis and polygonum cuspidatum. The composition is found to be capable of remarkably inhibiting a renin-angiotensin-aldosterone system, regulating vascular active factors, relaxing vascular smooth muscles, protecting vascular endothelial functions, reducing heart left ventricular hypertrophy and effectively reducing systolic pressure and diastolic pressure. The traditional Chinese medicine composition is an existing Chinese patent medicine, medication is safe, and the preparation method is simple, rapid, efficient and easy to operate. The prepared mixture, tablet, capsule, pellet and the like are convenient to carry and take.

Disclosed in the present invention are a pyrano-pyridine compound, a preparation method therefor, a pharmaceutical composition thereof and the use thereof. Provided in the present invention are a compound as shown in formula (I), a pharmaceutically acceptable salt thereof or a stereoisomer thereof. These compounds have a stronger inhibitory effect on aldosterone synthetase, but have almost no influence on cortisol synthetase, have high selectivity and higher safety, and can be used for preventing and / or treating various diseases related to aldosterone.

The invention discloses a metabolic marker aldosterone for screening heat stress Hu sheep as well as a screening method and application thereof, and belongs to the technical field of livestock serum markers. The metabolic marker for screening the heat stress Hu sheep is aldosterone; the screening method comprises the following steps: (1) taking blood of known heat-sensitive Hu sheep or heat-resistant Hu sheep as a standard test sample, taking blood of Hu sheep to be detected as a detection sample, and centrifuging to obtain a serum sample; (2) detecting the aldosterone concentration in the serum sample; and (3) calculating the aldosterone concentration average value of the standard test sample, taking the calculated aldosterone concentration critical value as a reference level, if the aldosterone concentration of the detection sample is higher than the reference level, determining that the detection sample is a heat-resistant Hu sheep, and if the aldosterone concentration of the detection sample is lower than the reference level, determining that the detection sample is a heat-sensitive Hu sheep. The aldosterone is used as the marker for detection, has the characteristics of high accuracy and high sensitivity, and can be directly used as an evaluation index for distinguishing the heat-sensitive Hu sheep from the heat-resistant Hu sheep.

The present invention relates to novel compounds and pharmaceutical compositions thereof, and to methods for promoting healthy skin aging, treating skin disorders, treating cardiovascular disorders, treating renal disorders, treating angiogenesis disorders, such as cancer, treating tissue damage, such as non-cardiac tissue damage, treating progressive myocardial infarction, and treating various other disorders, such as complications resulting from diabetes with the compounds and compositions of the invention. Other disorders may include, but are not limited to, atherosclerosis, coronary artery disease, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, skin infections, peripheral vascular disease, stroke, and the like.

The present disclosure relates to the use of angiotensin-converting enzyme and / or angiotensin-converting enzyme 2 as a fecal biomarker for the diagnosis of a disease or disorder related to the renin-angiotensin-aldosterone system, and also to the use of angiotensin-converting enzyme and angiotensin-converting enzyme 2 isoforms as fecal biomarkers for the detection of dysbiosis.

This application belongs to the field of immunoassay technology, and discloses an aldosterone sandwich antibody mAb5 or its antigen-binding fragment, its preparation method, and its applications. The aldosterone sandwich antibody mAb5 or its antigen-binding fragment includes a light chain variable region (VL) and a heavy chain variable region (VH). The light chain variable region (VL) includes complementarity-determining regions (LCDR1, LCDR2, and LCDR3), whose amino acid sequences are shown in SEQ ID NO. 1-3, respectively. The heavy chain variable region (VH) includes complementarity-determining regions (HCDR1, HCDR2, and HCDR3), whose amino acid sequences are shown in SEQ ID NO. 4-6, respectively. Using the aldosterone sandwich antibody mAb5 of this application to detect aldosterone standard antigens, the detection sensitivity is less than 7 pg / mL. Magnetochemiluminescence immunoassay of clinical samples shows good correlation with clinical results within the sample range of 0-1000 pg / mL, which is of great significance in the diagnosis and treatment of essential hypertension and other aldosterone-related diseases.

The application discloses a plant extraction compound for reducing blood pressure, a preparation method and application thereof. The compound is composed of high-purity silybin extract and a specific fusion polypeptide through molecular self-assembly. The sequence of the fusion polypeptide is shown in sequence SEQ ID NO:1, which innovatively integrates cell membrane penetration function, angiotensin II receptor 1 antagonism function and hydrophobic drug binding function. The core of the application is that through polypeptide-mediated active targeting, silybin is accurately delivered to the diseased blood vessel area, and the double synergistic mechanism of upstream ACE inhibition and downstream receptor blocking of the renin-angiotensin-aldosterone system is realized. In-vivo pharmacodynamic experiments prove that compared with single components, the compound can produce more significant and persistent antihypertensive effect, and can effectively reverse myocardial hypertrophy and fibrosis caused by hypertension, and show excellent synergistic therapeutic effect and target organ protection ability.

The present Invention relates to a newly designed product, i.e. substance (B+C) that combines two different mechanisms of action that allow the control of aldosterone synthesis and secretion without compromising the metabolism of cortisol (corticosterone In rats) in the.tone glomerulosa of the adrenal gland. The innovative design of the described molecule enables ths individual use of substance (B+C) in the treatment of diseases such as hyper and hypo aldosteronism, Conn's syndrome and cytokine storm caused by Covid infection or as co-therapy with corticosteroids in the treatment of a whole range of immunological diseases. The innovative design of Substance (8+C) has an additional practical and economic advantage because the patient receives both components of substance (B+C) simultaneously with just one application, regardless of the medicine formulation. This not only simplifies the medicine synthesis, dosing and clinical research, but also the application of the medicine in clinical practice. For successful and selective control of aldosterone synthesis, which in nature also means selective control of blood pressure, it was necessary to combine the two substances described in order to ensure action in patients with elevated and / or towered blood pressure with one application of Substance (B+C). This feature of Substance (B+C) is important, especially in the treatment of patients with permanently impaired aldosterone synthesis, such as Conn's disease and similar autoimmune diseases, or in combmatton with corticosteroids where prolonged or repeated corticosteroid therapy is indicated. Finally, this invention is extremely important because It enables the safe treatment of a large group of patients with hypertension who also have secondary diseases of the immune system, various inflammations or viral Infections such as Covid where corticosteroid therapy is indicated, but difficult to implement in practice due to the negative effect of corticosteroids on blood pressure.

The invention discloses a chronic kidney disease individualized and staged salt limiting method based on salt sensitivity, and relates to the technical field of individualized salt limiting. Making a preliminary standard salt limiting scheme; determining the actual salt intake condition; determining a salt threshold value of the patient; making an individualized stepped salt limiting scheme; the individualized and staged salt limiting method for the chronic kidney disease based on salt sensitivity has the advantages that through salt sensitivity detection, groups needing strict salt limiting can be recognized in an early stage, salt limiting can be conducted as soon as possible and reasonably, the method is beneficial for delaying renal function deterioration, the gradual salt limiting strategy is adopted, and the method is suitable for popularization and application. In combination with the salt threshold condition of a patient, stepped salt limitation is adopted, the clinical salt limitation compliance can be improved, and a small dose of aldosterone antagonist is combined on basic treatment for the patient of which the salt limitation does not reach the standard, so that the proteinuria reduction effect similar to that of enhanced salt limitation is achieved.

The invention relates to application of an activating agent in promotion of uranium element discharge. Specifically, the activating agent is prepared from rifampicin, erythromycin, progesterone, aldosterone, bilirubin, cholate vinblastine, doxomicin, adriamycin, paclitaxel, bosentan, ambrisentan, digoxin, verapamil, tonavir, amprenavir, indinavir, hypericum perforatum juice, curcumin, atorvastatin beclomethasone, budesonide, divaricasone carbamazepine and caffeine. And phenytoin. The use dosage of the activating agent is 10 to 60 mg / kg. According to the method, the accumulation amount of uranium in important organs such as bones and kidneys can be remarkably reduced, so that the potential toxic influence on the key organs is reduced.

Embodiments provide for methods of treatment for subjects suffering from a condition / disorder or disease for which the renin-angiotensin-aldosterone system (RAAS) plays at least some role. In one example, a method comprises administering to the subject an effective amount of one or more of an angiotensin receptor AT2R antagonist for a duration sufficient to elicit a desired response in the subject suffering from pancreatic cancer. The administering acts to reduce proliferation of tumor cells associated with the pancreatic cancer.

The application discloses a kind of medium chain inulin and its preparation method and application, belong to plant extraction technical field.The unique inulin structure and chain length disclosed in the application remodel intestinal microbiome and metabolome, especially selectively regulate key microorganisms such as coprococcus, bifidobacterium, parabacteroides, Clostridium_sensu_stricto_1 and Akkermansia, and metabolites such as nicotinamide, taurocholic acid, aldosterone, corticosterone, 2-(1H-indole-3-yl)acetic acid, 5-hydroxy-L-tryptophan, 5alpha-DHT and maltose, promote the improvement of host obesity and overall health status.The core microorganisms and metabolites identified by the technical scheme represent potential therapeutic targets for preventing or treating obesity and related metabolic symptoms.These findings support the development of inulin-based nutritional strategies to effectively manage weight by regulating specific microbiota and metabolome.

The purpose is to provide plasma biomarkers for bone infections in humans. [Solution] The plasma biomarker for bone infection consists of one or more substances selected from the group consisting of sphingosine-1-phosphate, taurocholic acid, glycololic acid, 11a,b-hydroxyprogesterone, 15(S)-HETE-2, 13-dehydrochenodeoxycholic acid, 3,21-dihydroxy-5a-pregnan-20-one-2, aldosterone, bisacrone-2, naringenin, tauro-a-muricholic acid-6, 1-deoxysphingosine, 12(S)-HETE-2, 2-arachidonoylglycerol, 3-hydroxydodecanoic acid, 3-hydroxytetradecanoic acid, 3b-hydroxy-5-cholestenoic acid, AEA(22:4)-1, AEA(22:4)-2, bilverdin, sphingosine, malic acid, and succinic acid.

To provide therapeutic methods for treating kidney diseases.SOLUTION: There are provided therapeutic methods for treating kidney diseases, using compounds of Formula (A) in combination with a second therapeutic agent. (In the formula: each R is independently selected from a group comprising H, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, heteroaryl, halogen, -OH, CN, cycloalkyl, -O-alkyl, -O-cycloalkyl, -O-aryl, -aryl-O-aryl, -CF3, -C(H)F2, alkylene-CF3, alkylene-C(H)F2, -SO2-alkyl, -O-alkylene-O-alkyl, -heterocyclyl-L-R4, and heteroaryl-L-R4; and only one R is -heterocyclyl-L-R4 or -heteroaryl-L-R4). The second therapeutic agent is selected from an immunomodulator, a calcineurin inhibitor, a renin angiotensin aldosterone system inhibitor, an antiproliferative agent, an alkylating agent, and the like.SELECTED DRAWING: None

The application discloses a nucleic acid aptamer and derivatives, application and kit capable of specifically combining with aldosterone, and comprises a nucleotide sequence shown in SEQ ID No. 1, or a nucleotide sequence with high homology with the nucleotide sequence shown in SEQ ID No. 1 and capable of specifically combining with aldosterone, or a nucleotide sequence derived from the nucleotide sequence shown in SEQ ID No. 1 and capable of specifically combining with aldosterone. The application provides a nucleic acid aptamer and derivatives capable of combining with aldosterone, which have high specificity, stable chemical properties, are easy to preserve and label, and also correspondingly provides a screening method and application of the nucleic acid aptamer.

The invention provides application of aldosterone in diagnosis of amyotrophic lateral sclerosis, and particularly provides application of a reagent for detecting the aldosterone level in a sample in preparation of products for in-vitro diagnosis, auxiliary diagnosis and / or illness monitoring of amyotrophic lateral sclerosis. By simply detecting the aldosterone level in a serum sample, accurate diagnosis and illness monitoring of ALS can be realized.

The invention relates to an in-vitro culture medium, an in-vitro culture method and application of a human amniotic fluid source organoid. The in-vitro culture medium of the human amniotic fluid source organoid comprises a DMEM-F12 basal culture medium, a glial cell source neurotrophic factor, 8-bromoadenosine-3 ', 5'-cyclic monophosphate and aldosterone. The culture medium provided by the invention is clear in component and high in culture success rate. The human amniotic fluid organ cultured by using the culture medium and the method disclosed by the invention can be differentiated into multiple types of functional cells including neuron-like cells, myocardial cells and the like through in-vitro induction, and the differentiation capacity is obviously superior to that of an existing 2D cell line model.

The invention relates to the technical field of molecular biology, and provides a marker combination for diagnosing neonatal necrotizing enterocolitis and application thereof. The marker combination comprises a CC chemokine ligand 20, a heparin binding epidermal growth factor, angiotensin and aldosterone. Four markers related to neonatal necrotizing enterocolitis are obtained through research and screening, whether neonatal necrotizing enterocolitis occurs or not and the severity of neonatal necrotizing enterocolitis can be effectively judged based on the markers, and the markers have high sensitivity and specificity and can be used for detecting neonatal necrotizing enterocolitis. The kit can help clinical diagnosis and prognosis of neonatal necrotizing enterocolitis.

The present invention detects and analyzes the technical field, and specifically relates to a high coverage analysis method for aldehyde and ketone compounds in liquor Daqu, comprising the following steps: one, obtaining chromatographic and mass spectrometric data information; two, constructing a QSRR prediction model; three, according to the chromatographic and mass spectrometric data information and the QSRR prediction model, analyzing the aldehyde and ketone compounds in the Daqu sample; wherein, the step one includes: ultrasonic extraction, derivatization and collection of chromatographic and mass spectrometric data information of aldehyde and ketone compounds in the Daqu sample by UHPLC-HRMS coupling technology; the reagent of the derivatization reaction includes: 2-hydrazine-4-chloropyridine, 2-hydrazine-3-chloropyridine, 2-hydrazine-5-chloropyridine, at least one of 2-hydrazine-6-chloropyridine. The method has the characteristics of high coverage, high sensitivity, good repeatability, etc. without the need to use expensive heavy isotope labeled derivatization reagents, and has significant advantages in the detection of aldehyde and ketone compounds.

The present invention provides a functional peptide with a blood pressure lowering effect, a preparation method and an application. The functional peptide provided by the present invention includes a peptide segment HPHLSFM, which has biological activity and can bind to angiotensin converting enzyme (ACE). ACE can catalyze angiotensin I to generate angiotensin II, which is a strong vasoconstrictor and an activator of adrenal cortical aldosterone release. At the same time, ACE also has the ability to decompose bradykinin (BK), which can weaken the vasodilator effect of BK, thereby leading to an increase in blood pressure in the blood circulation system. Therefore, after the functional peptide is combined with ACE, it can play a role in lowering blood pressure by inhibiting the function of ACE.

Provided herein is a pharmaceutical composition for treating resistant hypertension, which includes amlodipine, chlorthalidone, and amiloride. This disclosure also provides an application of the pharmaceutical composition in the treatment of low renin / low aldosterone resistant hypertension and targeting organ damage in the subject suffering from resistant hypertension.

The present invention provides a combination comprising (a) a sulfonylurea; and (b) at least one of the following components: (i) an insulin modulator and (ii) an aldosterone antagonist, for example in combinations comprising (a) glibenclamide or a structural or functional analog thereof; and (b) at least one of the following components: (i) exenatide or a structural or functional analogue thereof or a pharmaceutically acceptable salt thereof; and (ii) potassium canlylate or a structural or functional analogue thereof. The combination is suitable for use in the treatment of stroke and other neurodegenerative conditions, as well as in the treatment and / or prevention of ischemia and / or reperfusion injury of various important organs, including the brain and heart. Other aspects of the invention relate to pharmaceutical products and pharmaceutical compositions comprising the combination according to the invention, as well as methods of treatment using the same.